Healthia Management

Management criteria checks 3/4

Healthia's CEO is Wes Coote, appointed in Apr 2019, has a tenure of 4.67 years. total yearly compensation is A$660.60K, comprised of 60.2% salary and 39.8% bonuses, including company stock and options. directly owns 1.42% of the company’s shares, worth A$3.58M. The average tenure of the management team and the board of directors is 1.4 years and 5.6 years respectively.

Key information

Wes Coote

Chief executive officer

AU$660.6k

Total compensation

CEO salary percentage60.2%
CEO tenure4.7yrs
CEO ownership1.4%
Management average tenure1.4yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Calculating The Fair Value Of Healthia Limited (ASX:HLA)

Jan 30
Calculating The Fair Value Of Healthia Limited (ASX:HLA)

Healthia (ASX:HLA) Has Re-Affirmed Its Dividend Of AU$0.02

Mar 02
Healthia (ASX:HLA) Has Re-Affirmed Its Dividend Of AU$0.02

Here's Why Healthia Limited's (ASX:HLA) CEO May Deserve A Raise

Nov 09
Here's Why Healthia Limited's (ASX:HLA) CEO May Deserve A Raise

Earnings Tell The Story For Healthia Limited (ASX:HLA) As Its Stock Soars 30%

Sep 17
Earnings Tell The Story For Healthia Limited (ASX:HLA) As Its Stock Soars 30%

Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Sep 17
Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

Sep 01
Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

I Ran A Stock Scan For Earnings Growth And Healthia (ASX:HLA) Passed With Ease

Aug 17
I Ran A Stock Scan For Earnings Growth And Healthia (ASX:HLA) Passed With Ease

Is Now An Opportune Moment To Examine Healthia Limited (ASX:HLA)?

May 19
Is Now An Opportune Moment To Examine Healthia Limited (ASX:HLA)?

Is Healthia (ASX:HLA) A Risky Investment?

Apr 19
Is Healthia (ASX:HLA) A Risky Investment?

With EPS Growth And More, Healthia (ASX:HLA) Is Interesting

Apr 03
With EPS Growth And More, Healthia (ASX:HLA) Is Interesting

Announcing: Healthia (ASX:HLA) Stock Increased An Energizing 108% In The Last Year

Mar 19
Announcing: Healthia (ASX:HLA) Stock Increased An Energizing 108% In The Last Year

Insider Buying: The Healthia Limited (ASX:HLA) Independent Non-Executive Director Just Bought 4.7% More Shares

Mar 06
Insider Buying: The Healthia Limited (ASX:HLA) Independent Non-Executive Director Just Bought 4.7% More Shares

What Kind Of Shareholders Hold The Majority In Healthia Limited's (ASX:HLA) Shares?

Feb 26
What Kind Of Shareholders Hold The Majority In Healthia Limited's (ASX:HLA) Shares?

Is There Now An Opportunity In Healthia Limited (ASX:HLA)?

Feb 09
Is There Now An Opportunity In Healthia Limited (ASX:HLA)?

Healthia Limited's (ASX:HLA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Jan 19
Healthia Limited's (ASX:HLA) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Why Dividend Hunters Love Healthia Limited (ASX:HLA)

Dec 29
Why Dividend Hunters Love Healthia Limited (ASX:HLA)

Did You Miss Healthia's (ASX:HLA) 13% Share Price Gain?

Dec 10
Did You Miss Healthia's (ASX:HLA) 13% Share Price Gain?

We're Not So Sure You Should Rely on Healthia's (ASX:HLA) Statutory Earnings

Nov 20
We're Not So Sure You Should Rely on Healthia's (ASX:HLA) Statutory Earnings

CEO Compensation Analysis

How has Wes Coote's remuneration changed compared to Healthia's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023AU$661kAU$398k

AU$5m

Mar 31 2023n/an/a

AU$3m

Dec 31 2022n/an/a

AU$781k

Sep 30 2022n/an/a

-AU$1m

Jun 30 2022AU$516kAU$345k

-AU$3m

Mar 31 2022n/an/a

-AU$2m

Dec 31 2021n/an/a

AU$161k

Sep 30 2021n/an/a

AU$3m

Jun 30 2021AU$400kAU$306k

AU$5m

Mar 31 2021n/an/a

AU$6m

Dec 31 2020n/an/a

AU$7m

Sep 30 2020n/an/a

AU$5m

Jun 30 2020AU$313kAU$225k

AU$3m

Mar 31 2020n/an/a

AU$1m

Dec 31 2019n/an/a

AU$271k

Sep 30 2019n/an/a

-AU$483k

Jun 30 2019AU$226kAU$176k

-AU$1m

Compensation vs Market: Wes's total compensation ($USD439.78K) is about average for companies of similar size in the Australian market ($USD622.80K).

Compensation vs Earnings: Wes's compensation has been consistent with company performance over the past year.


CEO

Wes Coote

4.7yrs

Tenure

AU$660,599

Compensation

Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...


Leadership Team

NamePositionTenureCompensationOwnership
Wesley Coote
Group MD4.7yrsAU$660.60k1.42%
A$ 3.6m
Damien Peters
Group Chief Financial Officerless than a yearAU$319.83kno data
Darren Stewart
Director of Podiatry & Executive Directorno dataAU$115.34k6.4%
A$ 16.1m
Lisa Roach
Group Chief Partnerships Officer & Executive Directorless than a yearAU$391.84k0.75%
A$ 1.9m
Colin Kangisser
CEO of Eyes & Ears Division and Director2.7yrsAU$368.92k3.66%
A$ 9.2m
Roy Walker
Chief Executive Officer of Bodiesless than a yearAU$314.24kno data
Dean Hartley
Chief Technology Officer1.9yrsAU$261.49k2.49%
A$ 6.3m
Julia Murfitt
General Counsel & Company Secretary1.8yrsno datano data
Anthony Ganter
Group Chief Business Development & Strategy Officerno dataAU$341.32k0%
A$ 0
Kerrie Evans
Group Chief Education & Research Officerno datano datano data
Aaron Kangisser
Chief Operating Officer of Eyes & Ears Divisionless than a yearno datano data

1.4yrs

Average Tenure

Experienced Management: HLA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Wesley Coote
Group MD4.7yrsAU$660.60k1.42%
A$ 3.6m
Darren Stewart
Director of Podiatry & Executive Director5.6yrsAU$115.34k6.4%
A$ 16.1m
Lisa Roach
Group Chief Partnerships Officer & Executive Director1.7yrsAU$391.84k0.75%
A$ 1.9m
Colin Kangisser
CEO of Eyes & Ears Division and Director2.7yrsAU$368.92k3.66%
A$ 9.2m
Glen Richards
Non-Executive Chairman5.6yrsAU$130.00k5.67%
A$ 14.3m
Paul Wilson
Independent Non-Executive Director5.6yrsAU$80.00k2.51%
A$ 6.3m
Lisa Dalton
Independent Non-Executive Director5.6yrsAU$80.00k0.034%
A$ 85.2k

5.6yrs

Average Tenure

Experienced Board: HLA's board of directors are considered experienced (5.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/04 03:32
End of Day Share Price 2023/11/30 00:00
Earnings2023/06/30
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Healthia Limited is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Warren JeffriesCanaccord Genuity
Wilson WongJarden Limited